<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090267</url>
  </required_header>
  <id_info>
    <org_study_id>CED000000532</org_study_id>
    <secondary_id>P01AA029543</secondary_id>
    <secondary_id>PRO00035889</secondary_id>
    <nct_id>NCT05090267</nct_id>
  </id_info>
  <brief_title>The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study</brief_title>
  <official_title>Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Exegi Pharma, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soterix Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project uses a hybrid trial design to evaluate two biomedical interventions targeting&#xD;
      the gut-brain axis. One intervention is portable Transcutaneous Vagus Nerve Stimulator, tVNS,&#xD;
      that is hypothesized to stimulate the autonomic nervous system, resulting in decreased&#xD;
      inflammation and improved cognition. The second intervention is a probiotic supplement&#xD;
      intended to replace gut bacteria that are associated with dysbiosis in persons with HIV and&#xD;
      alcohol consumption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This is a 2 x 2 factorial, longitudinal design (tVNS/Sham, Probiotic/Placebo) across three time points (baseline; 30days and 90days).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a 2x2 design in which subjects will be randomly assigned to one of 4 interventions groups: tVNS and probiotic (n=20); tVNS and placebo (n=20), sham stimulator and probiotic (n=20), and sham stimulator and placebo (n=20). We will use a computer-assisted stratified block randomization with block size of 4 to assign participants to the intervention. Study participants, investigators, staff, and physicians administering the probiotics or placebo will be unaware of specific group assignment. The stratified, blocked randomization and assignment of participants to the 4 intervention groups will be guided and monitored by Data Science Core.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improved cognition from day 1 to day 90</measure>
    <time_frame>Baseline up to 90 days</time_frame>
    <description>Various indices of cognition will be measured using standard neuropsychological tests and neuroimaging at multiple time points and examined for change within subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of dysbiosis from day 1 to day 90</measure>
    <time_frame>Baseline up to 90 days</time_frame>
    <description>The gut microbiome will be analyzed through stool samples to measure for changes in biodiversity including an increase in beneficial bacteria.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cognition</condition>
  <condition>Gut Microbiome</condition>
  <arm_group>
    <arm_group_label>Dietary Supplement (e.g., vitamins, minerals)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visbiome probiotic supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device (including sham)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcutaneous Vagal Nerve Stimulation (tVNS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic Supplement</intervention_name>
    <description>Participants will take a probiotic supplement or placebo for 90 days.</description>
    <arm_group_label>Dietary Supplement (e.g., vitamins, minerals)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous Vagal Nerve Stimulation (tVNS)</intervention_name>
    <description>Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.</description>
    <arm_group_label>Device (including sham)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 35-70 years&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Alcohol users&#xD;
&#xD;
          -  Cognitive impairment&#xD;
&#xD;
          -  Current CD4&gt;350&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed major psychiatric illness&#xD;
&#xD;
          -  Consumption of over 300 drinks in the past 30 days&#xD;
&#xD;
          -  Recent opioid use&#xD;
&#xD;
          -  Lifetime history of medically-assisted alcohol detoxification&#xD;
&#xD;
          -  Inpatient or intensive treatment for addictive behaviors in the past 12 months&#xD;
&#xD;
          -  MRI contraindications&#xD;
&#xD;
          -  Current antibiotic treatment&#xD;
&#xD;
          -  Current probiotic use&#xD;
&#xD;
          -  Physical impairment precluding motor response or lying still.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Porges, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert L Cook, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taylor LeCorgne</last_name>
    <phone>352-273-9562</phone>
    <email>tlecorgne@ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Varan Govind, PhD</last_name>
      <phone>305-243-8096</phone>
      <email>vgovind@umail.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Varan Govind, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

